Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.

Nature communications - 19 May 2016

Wang Jieqiong, Hu Kewen, Guo Jiawei, Cheng Feixiong, Lv Jing, Jiang Wenhao, Lu Weiqiang, Liu Jinsong, Pang Xiufeng, Liu Mingyao

Abstract excerpt

No effective targeted therapies exist for cancers with somatic KRAS mutations. Here we develop a synthetic lethal chemical screen in isogenic KRAS-mutant and wild-type cells to identify clinical drug pairs. Our results show that dual inhibition of polo-like kinase 1 and RhoA/Rho kinase (ROCK) leads to the synergistic effects in KRAS-mutant cancers. Microarray analysis reveals that this combinatory inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to G2 Phase

Share to Mice, Inbred BALB C

Share to Polo-Like Kinase 1

Share to Proto-Oncogene Proteins p21(ras)

Share to rho-Associated Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 27193833
DOI: 10.1038/ncomms11363
PMCID: PMC4873974

Genes

KRAS
PLK1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.PMID 27193833Read ↗

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.Semantic proximity Read ↗

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Semantic proximity Read ↗

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.Semantic proximity Read ↗

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Semantic proximity Read ↗

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Semantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.Semantic proximity Read ↗

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.Semantic proximity Read ↗

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.